R. P. Marques, G. S. Duarte, C. Sterrantino, H. L. Pais, A. Quintela et al., Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis, Crit Rev Oncol Hematol, vol.118, pp.54-62, 2017.
DOI : 10.1016/j.critrevonc.2017.08.006

M. Loriot, J. Ciccolini, F. Thomas, C. Barin-le-guellec, B. Royer et al., Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks

, Bull Cancer (Paris), 2018.

J. Zhang, L. Zhang, Y. Yan, S. Li, L. Xie et al., Are capecitabine and the active metabolite 5

, Fu CNS penetrable to treat breast cancer brain metastasis? Drug Metab Dispos Biol Fate Chem, vol.43, pp.411-418, 2015.

J. Yuan, H. Lv, B. Peng, C. Wang, Y. Yu et al., Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer, Cancer Chemother Pharmacol, vol.63, issue.6, pp.1103-1113, 2009.

J. Yuan, J. Cheng, L. Jiang, J. Guo, L. Liu et al., Breast cancer resistance protein expression and 5-fluorouracil resistance, Biomed Environ Sci BES, vol.21, issue.4, pp.290-295, 2008.

M. Kool, M. De-haas, G. L. Scheffer, R. J. Scheper, M. J. Van-eijk et al., Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines, Cancer Res, vol.57, issue.16, pp.3537-3584, 1997.

W. Hagmann, R. Faissner, M. Schnölzer, M. Löhr, and R. Jesnowski, Membrane drug transporters and chemoresistance in human pancreatic carcinoma. Cancers, vol.3, pp.106-131, 2010.

L. J. Schaaf, B. R. Dobbs, I. R. Edwards, and D. G. Perrier, Nonlinear pharmacokinetic characteristics of 5fluorouracil (5-FU) in colorectal cancer patients, Eur J Clin Pharmacol, vol.32, issue.4, pp.411-419, 1987.

G. Milano, M. C. Etienne, E. Cassuto-viguier, A. Thyss, J. Santini et al., Influence of sex and age on fluorouracil clearance, J Clin Oncol Off J Am Soc Clin Oncol, vol.10, issue.7, pp.1171-1176, 1992.

M. C. Etienne, J. L. Lagrange, O. Dassonville, R. Fleming, A. Thyss et al., Population study of dihydropyrimidine dehydrogenase in cancer patients, J Clin Oncol Off J Am Soc Clin Oncol, vol.12, issue.11, pp.2248-53, 1994.

K. Morawska, F. Goirand, L. Marceau, M. Devaux, A. Cueff et al., 5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer, Oncotarget, vol.9, issue.14, pp.11559-71, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01737921

M. C. Etienne, E. Chatelut, X. Pivot, M. Lavit, A. Pujol et al., Co-variables influencing 5fluorouracil clearance during continuous venous infusion. A NONMEM analysis, Eur J Cancer Oxf Engl, vol.34, issue.1, pp.92-99, 1990.

F. J. Ansfield, J. M. Schroeder, and A. R. Curreri, Five Years Clinical Experience with 5-Fluorouracil, JAMA, vol.181, issue.4, pp.295-304, 1962.

R. A. Fleming, G. A. Milano, M. C. Etienne, N. Renée, A. Thyss et al., No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion, Br J Cancer, vol.66, issue.4, pp.668-72, 1992.

C. Terret, E. Erdociain, R. Guimbaud, M. Boisdron-celle, H. L. Mcleod et al., Dose and time dependencies of 5-fluorouracil pharmacokinetics, Clin Pharmacol Ther, 2000.

E. Gamelin, M. Boisdron-celle, V. Guérin-meyer, R. Delva, A. Lortholary et al., Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage, J Clin Oncol Off J Am Soc Clin Oncol, vol.17, issue.4, p.1105, 1999.

J. Saam, G. C. Critchfield, S. A. Hamilton, B. B. Roa, R. J. Wenstrup et al., Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens, Clin Colorectal Cancer, vol.10, issue.3, pp.203-209, 2011.

A. Ismail, M. G. Quinn, M. A. Wright, A. Ernst, V. Kao et al., A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel, Oncol Rep, vol.13, issue.6, pp.1145-52, 2005.

J. L. Grem, M. Quinn, A. S. Ismail, C. H. Takimoto, R. Lush et al., Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion, Cancer Chemother Pharmacol, vol.47, issue.2, pp.117-142, 2001.

F. S. Braiteh, S. J. Salamone, Y. Li, J. B. Courtney, M. Duda et al., Pharmacokinetic (PK)-guided optimization of 5-fluorouracil (5FU) exposure in colorectal cancer (CRC) patients: U.S.-based clinical practices experience, J Clin Oncol, vol.32, pp.3574-3574, 2014.

C. Kline, A. Schiccitano, J. Zhu, C. Beachler, H. Sheikh et al., Personalized Dosing via Pharmacokinetic Monitoring of 5-Fluorouracil Might Reduce Toxicity in Early-or Late-Stage Colorectal Cancer Patients Treated With Infusional 5-Fluorouracil-Based Chemotherapy Regimens, Clin Colorectal Cancer, vol.13, issue.2, pp.119-145, 2014.

J. Santini, G. Milano, A. Thyss, N. Renee, P. Viens et al., 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer, Br J Cancer, vol.59, issue.2, pp.287-90, 1989.

E. Gamelin, M. Boisdron-celle, R. Delva, C. Regimbeau, P. E. Cailleux et al., Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients, J Clin Oncol Off J Am Soc Clin Oncol, vol.16, issue.4, pp.1470-1478, 1998.

M. Wilhelm, L. Mueller, M. C. Miller, K. Link, S. Holdenrieder et al., Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice, Clin Colorectal Cancer, 2016.

E. Gamelin, R. Delva, J. Jacob, Y. Merrouche, J. L. Raoul et al., Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer, J Clin Oncol, vol.26, issue.13, pp.2099-105, 2008.

R. Becker, C. S. Hollenbeak, A. Choma, P. Kenny, and S. J. Salamone, Cost-Effectiveness Of Pharmacokinetic Dosing Of 5-Fluorouracil In Metastatic Colorectal Cancer In The United Kingdom. Value Health, vol.16, p.139, 2013.

D. A. Goldstein, Q. Chen, T. Ayer, D. H. Howard, J. Lipscomb et al., Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer, Clin Colorectal Cancer, vol.13, issue.4, pp.219-244, 2014.

A. Thyss, G. Milano, N. Renée, J. Vallicioni, M. Schneider et al., Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer, Cancer Chemother Pharmacol, vol.16, issue.1, pp.64-70, 1986.

G. Milano, M. C. Etienne, N. Renée, A. Thyss, M. Schneider et al., Relationship between fluorouracil systemic exposure and tumor response and patient survival, J Clin Oncol Off J Am Soc Clin Oncol, vol.12, issue.6, pp.1291-1296, 1994.
DOI : 10.1200/jco.1994.12.6.1291

M. Beneton, S. Chapet, H. Blasco, B. Giraudeau, M. Boisdron-celle et al., Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy, Br J Clin Pharmacol, 2007.
DOI : 10.1111/j.1365-2125.2007.02951.x

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2007.02951.x/pdf

R. R. Kaldate, A. Haregewoin, C. E. Grier, S. A. Hamilton, and H. L. Mcleod, Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6. The Oncologist, vol.17, pp.296-302, 2012.

M. Boisdron-celle, L. Guellec, and C. , Niveau de preuve du suivi thérapeutique pharmacologique du 5fluorouracile au décours de son administration dans le traitement des cancers des voies aérodigestives supérieures et du cancer colorectal, Thérapie, vol.65, issue.3, pp.171-177, 2010.
DOI : 10.2515/therapie/2010023

E. Petit, G. Milano, F. Lévi, A. Thyss, F. Bailleul et al., Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients, Cancer Res, vol.48, issue.6, pp.1676-1685, 1988.

F. A. Lévi, R. Zidani, J. M. Vannetzel, B. Perpoint, C. Focan et al., Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multiinstitutional trial, J Natl Cancer Inst, vol.86, issue.21, pp.1608-1625, 1994.

G. F. Fleming, P. Schumm, G. Friberg, M. J. Ratain, U. O. Njiaju et al., Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion, BMC Cancer
DOI : 10.1186/s12885-015-1075-6

URL : https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-015-1075-6?site=bmccancer.biomedcentral.com

B. Jacobs, M. J. Deenen, D. Pluim, J. Van-hasselt, M. D. Krähenbühl et al., Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers, Br J Clin Pharmacol, 2016.
DOI : 10.1111/bcp.13007

URL : http://onlinelibrary.wiley.com/doi/10.1111/bcp.13007/pdf

R. F. Murphy, F. M. Balis, and D. G. Poplack, Stability of 5-fluorouracil in whole blood and plasma, Clin Chem, vol.33, issue.12, pp.2299-300, 1987.

E. Gamelin, M. Boisdron-celle, A. Turcant, F. Larra, P. Allain et al., Rapid and sensitive highperformance liquid chromatographic analysis of halogenopyrimidines in plasma, J Chromatogr B Biomed Sci App, vol.695, issue.2, pp.409-425, 1997.
DOI : 10.1016/s0378-4347(97)00211-9

D. Montange, M. Bérard, M. Demarchi, P. Muret, S. Piédoux et al., An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma, J Mass Spectrom JMS, vol.45, issue.6, pp.670-677, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00508032

P. Deng, C. Ji, X. Dai, D. Zhong, L. Ding et al., Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatographytandem mass spectrometry, J Chromatogr B Analyt Technol Biomed Life Sci, vol.989, pp.71-80, 2015.

J. L. Holleran, J. L. Eiseman, R. A. Parise, S. Kummar, and J. H. Beumer, LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma, J Pharm Biomed Anal, vol.129, pp.359-66, 2016.

O. Chavani, B. P. Jensen, R. M. Strother, C. M. Florkowski, and P. M. George, Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, ?-fluoro-?-ureidopropionic acid and ?-fluoro-?-alanine in human plasma, J Pharm Biomed Anal, vol.142, pp.125-160, 2017.

J. H. Beumer, M. Boisdron-celle, C. W. Courtney, J. B. Egorin, M. J. Gamelin et al., Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer, Ther Drug Monit, vol.31, issue.6, pp.688-94, 2009.